



PRESS RELEASE

## ENOBRAQ HIRES CHRISTOPHE DARDEL AS NEW CEO TO SUSTAIN ENOBRAQ'S AMBITION

Ramonville Saint Agne, April 27<sup>th</sup> 2017 – EnobraQ is proud to announce the appointment of Christophe Dardel as new CEO of EnobraQ. He is replacing Michael Krel who has been acting CEO since EnobraQ's inception late 2015. Consequently, Michael will resume his duty at Sofinnova and will also act as board member of EnobraQ.

Christophe's mission will be to crystalize the company's ambition to unlock the use of CO<sub>2</sub> as an industrial fermentation feedstock enabling large commodity chemicals to be produced in a sustainable manner, both economically and ecologically.

Christophe Dardel was previously the President of DSM Biomedical located in the USA where he was responsible for leading the business's global activities that included the acquisition of Kensey Nash, a leading regenerative medicine company. Christophe was also Board Member of Actamax® a DSM/DuPont Joint Venture.

Before joining DSM Biomedical in May 2010, Christophe served for eight years as President of DSM Dyneema, the inventor and manufacturer of Dyneema®, the world's strongest fiber™. In 2003 he was also appointed board member of Nippon Dyneema Co., Ltd - a joint venture of Toyobo and DSM.

Prior to joining DSM in 2002, Christophe held several positions within 3M and E. I. du Pont de Nemours

Christophe Dardel adds "I am very proud to join EnobraQ to bring its vision to reality: transforming the world by enabling the use of CO<sub>2</sub> as a carbon feedstock for the chemical industry. By doing so with an industrially proven microorganism, we really think we can have an impact on the global greenhouse gases issue"

Leopold Demideleer, chairman of the board, concludes: "We are very excited to welcome Christophe at EnobraQ. His outstanding international business experience is now needed to boost our small start-up to the next development stage".

### About EnobraQ

EnobraQ is a French metabolic engineering start up founded in 2015 leveraging patented pending breakthrough technologies developed within the Toulouse White Biotech cluster (TWB). EnobraQ is unlocking the use of CO<sub>2</sub> as an industrial fermentation feedstock enabling large commodity chemicals to be produced in a sustainable manner, both economically and ecologically.

#### Press contacts :

OXYGEN Agency - Mélissa Pontéry / Aurélie Vérin  
Tél : +33 (0)5 32 11 07 36 / [melissap@oxygen-rp.com](mailto:melissap@oxygen-rp.com) / [@melissapontery](https://www.instagram.com/melissapontery)